KYTX Stock: Kyverna Therapeutics, Inc. Stock Price, Analysis & Insights
Get live kytx stock price $6.91, comprehensive Kyverna Therapeutics, Inc. stock analysis, charts, news, and expert forecast. Real-time kytx stock data and investment insights.
Loading chart...
Company Overview
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Company Information
- CEO
- Warner Biddle
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 112
Contact Information
- Website
- https://kyvernatx.com
- Address
- 5980 Horton Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 3.69)
Business Model & Strategy
Kyverna Therapeutics, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Warner Biddle, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Kyverna Therapeutics, Inc. competes in the Biotechnology within the broader Healthcare. With 302.6 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Kyverna Therapeutics, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Kyverna Therapeutics, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Kyverna Therapeutics, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Kyverna Therapeutics, Inc.
- ⚠Investors should consider how Kyverna Therapeutics, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
302.60M
P/E Ratio
-1.85
Beta
3.69
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 302.60M market capitalization
- Trading Volume: 15.53M shares traded today
- Price Range: 52-week range of $1.78 - $13.67
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. (KYTX) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 302.60M, the company represents a significant player in its market. The stock is currently trading at $6.91 with a negativedaily change of 32.52%.
The company's 112 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -1.85, beta of 3.69, and 52-week price range from $1.78 to $13.67when evaluating investment opportunities.
Why Invest in Kyverna Therapeutics, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Warner Biddle
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.